Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Arrowhead Research Corp (ARWR): Bridger Management Builds 5.5% Passive Stake

Roberto Mignone’s Bridger Management has amassed a 5.5% stake in Arrowhead Research Corp (NASDAQ:ARWR) according to a 13G filing with the Securities and Exchange Commission on January 23. Bridger Management now owns 2.98 million Arrowhead shares as of the time of the filing.


Mignone was one of the 23 hedge fund managers profiled in Katherine Burton’s 2007 novel Hedge Hunters. In it, she described the very meticulous and calculated way in which Mignone manages his fund, which the Harvard Business School grad started in 2000. Bridger maintains a very balanced equity portfolio of approximately 30 long positions and 60 short positions, with each of those holdings limited in size so that the overall gross exposure never exceeds 200%, while the net exposure falls between 20% and 60%. As of September 30, Bridger’s equity portfolio was valued at $1.47 billion. 

The position in Arrowhead Research Corp (NASDAQ:ARWR) is a new one for Bridger, which reporting no position in the company as of September 30, according to their most recent 13F filing. The strong push into another pharmaceutical stock is nothing new for the fund, which has placed a high emphasis on the healthcare sector.

As we reported in October, Bridger has greatly increased their position in The Medicines Company (NASDAQ:MDCO), upping their stake from 1.86 million shares as of June 30, to 3.3 million shares by early October, nearly doubling their position. That elevated The Medicines Company to the top position in their equity portolio as of September 30, representing 4.72% of its total value. Bridger also has strong positions in Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) with 1.21 million shares, and Envision Healthcare Holdings Inc (NYSE:EVHC) with 1.74 million shares. Both of those positions were greatly increased during the third quarter of 2014, with Teva’s increasing 62%, and Envision’s up 30%.